Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Dermatology
  • Dermatology News
  • Low-dose oral...

Low-dose oral minoxidil initiation for patients with hair loss: International modified Delphi consensus statement

Dr. Kamal Kant KohliWritten by Dr. Kamal Kant Kohli Published On 2024-11-22T07:00:11+05:30  |  Updated On 22 Nov 2024 12:42 PM IST
hair loss
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Hair loss significantly impacts patients' quality of life, and it may be nonscarring or scarring. Etiologically, hair loss may be hereditary (androgenetic alopecia [AGA]); related to age; congenital (hair shaft disorders); traction induced; inflammatory (primary scarring alopecia); autoimmune (alopecia areata); or secondary to medical, surgical, or emotional stressors (telogen effluvium), infection (tinea capitis), and certain medica- tions including cancer therapies.

Topical minoxidil is approved by the US Food and Drug Admin- istration (FDA) as an over-the-counter drug designed to treat male pa- tients with AGA (minoxidil, 5% solution, or minoxidil, 5% foam, twice daily) and female patients with AGA (minoxidil, 2% solution, twice daily, or minoxidil, 5% foam, once daily). It is also frequently prescribed off-label for other types of hair loss in children and adults. Common adverse effects include transient shedding with initiation, hypertrichosis, and contact dermatitis, most commonly secondary to nonactive formulary ingredients, such as propylene glycol.

Minoxidil, a potent peripheral vasodilator, was originally ap- proved by the FDA in 1979 as an oral agent for patients with severe refractory hypertension with antihypertensive dosing ranging from 10 mg to 40 mg daily. Interestingly, a significant adverse effect of oral minoxidil was hypertrichosis, leading to the development of topical minoxidil as a hair growth agent in the 1980s.

Minoxidil exerts its effects via various proposed pathways: (1) a vasodilator acting on adenosine triphosphate–sensitive potassium channels, (2) an anti-inflammatory agent, (3) inducer of the Wnt/β- catenin signaling pathway, (3) a 5-α reductase inhibitor and antiandro- gen, and (4) an anagen extender.6 Topical minoxidil is converted into its active form, minoxidil sulfate, via sulfotransferase enzyme activity in the outer root sheath of hair follicles, and oral minoxidil is absorbed in the gastrointestinal tract and converted to its activated sulfated form in the liver.6 The systemic absorption of topical minoxidil is negligible, well below the minimum level of 20.0 ng per millimeter, at which hemodynamic changes in blood pressure have been documented.2 Oral minoxidil reaches peak levels in plasma within an hour, has a half-life of 3 to 4 hours, and is excreted by the kidneys within 12 to 20 hours.6

Oral minoxidil is not a first-line antihypertensive agent due to the risk for fluid retention, tachycardia, and other potential adverse effects, such as pericardial and pleural effusion, cardiac tamponade, and angina pectoris, with antihypertensive dosing.7 However, a grow- ing number of research groups have reported on the off-label use of low-dose oral minoxidil (LDOM), ranging from 0.25 mg to 5 mg daily, as a safe and effective treatment option for male and female pa- tients with AGA, age-related patterned thinning, traction alopecia, alopecia areata, telogen effluvium, scarring, and other forms of hair loss, though some serious adverse effects have been reported. This correlates with an increased demand for LDOM pre- scriptions in recent years.16 As the current data on LDOM initiation and monitoring for hair loss are limited, there is a pressing need for an ex- pert consensus–based statement for common use to maximize hair growth and minimize cardiovascular and other adverse effects.

Dermatologists with hair loss expertise, identified by clinical ex- perience, research activities, and participation in recognized pro- fessional societies, including the North American Hair Research Society, International Federation of Hair Research Societies, and World Congress for Hair Research, were invited via email to join the LOMI expert panel and engage in multiple survey rounds address- ing LDOM safety, efficacy, dosing, and monitoring for treating pa- tients with hair loss. Experts were encouraged to answer items based on their clinical expertise and experience with LDOM; relevant lit- erature was provided for review. To minimize bias, individual ex- pert responses were anonymous from all except the study coordi- nator (Y.M.A.). Based on consensus parameters set by prior Delphi studies, consensus for a LOMI item was defined as at least 70% of experts indicating agree or strongly agree on a 5-point Likert scale.

The initial survey round included items that were non–Likert scale (demographic, open-ended, or multiple choice), as well as items requiring a Likert scale response (strongly disagree, disagree, neu- tral, agree, strongly agree; Figure). After each round, aggregated re- sponses were reviewed by the multidisciplinary LOMI steering com- mittee, and feedback was provided to the LOMI expert panel. When indicated, survey items were revised for clarification or to incorpo- rate expert comments and submitted for expert review in subse- quent rounds. In rounds and survey items were calibrated ation, or did not achieve at least 70% consensus, were either re- vised or reconsidered in subsequent rounds or eliminated.

Reference:

Akiska YM, Mirmirani P, Roseborough I, et al. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement. JAMA Dermatol. Published online November 20, 2024. doi:10.1001/jamadermatol.2024.4593

JAMA Dermatologyminoxidilhair lossalopecia areata
Source : JAMA Dermatology
Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Show Full Article
Next Story

Editorial

Featured image representing medico legal

What's the Role of Expert Opinion in Medical Negligence?

7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

Darbapoetin Alfa In Chemotherapy Induced Anaemia: Check out 5 takeaways from recent study

Darbapoetin Alfa In Chemotherapy Induced Anaemia: Check out 5 takeaways from recent study

Biosimilar Denosumab of Alkem (Denuril) shows Comparable Efficacy in Treating Postmenopausal Osteoporosis in Indian Women

Biosimilar Denosumab of Alkem (Denuril) shows Comparable Efficacy in Treating Postmenopausal...

View All

Journal Club Today

Medical Journalism: Need of the Hour - Ft: Dr Prem Aggarwal (Chairman, Medical Dialogues), Dr Nandita Mohan (Head, MDTV Division, Medical Dialogues)

Medical Journalism: Need of the Hour - Ft: Dr Prem Aggarwal (Chairman, Medical Dialogues), Dr...

View All

Health News Today

Health Bulletin 08/ May/ 2025

Health Bulletin 08/ May/ 2025

View All
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok